Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon
plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected
recipients and reduce the risk of recurrent HCV and allograft hepatitis following liver
transplant.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)